GRAF FINCKENSTEIN FRIEDRICH 4

What Happened
Graf Finckenstein, Chief Medical Officer of Iovance Biotherapeutics (IOVA), had 31,246 restricted stock units (RSUs) vest on March 5, 2026. The RSUs converted into common stock at a $0.00 exercise price (typical for RSU vesting). To satisfy tax withholding, 16,520 shares were withheld by the company at $4.58 per share (total ~$75,662), leaving 14,726 shares issued to the insider.

Key Details

• Transaction date: March 5, 2026; Form filed March 6, 2026.
• Vesting/Conversion: 31,246 RSUs -> 31,246 common shares (code M, $0.00).
• Tax withholding: 16,520 shares withheld (code F) at $4.58/share = $75,662 (this is not an open‑market sale).
• Net shares delivered to insider after withholding: 14,726 shares.
• Relevant footnotes: RSUs vested on the transaction date; withheld shares satisfy mandatory tax withholding (not a market sale); each RSU equals one share; remaining RSUs vest quarterly and reflect the remainder of the March 5, 2025 grant.
• Filing timeliness: filed one day after the transaction date (appears timely).

Context
This was a routine vesting of RSUs (an award), not an open‑market purchase or sell order. The company withheld shares to cover taxes (a net settlement), which is common and does not necessarily indicate the insider sold shares on the market. Remaining RSUs from the referenced grant will continue to vest in equal quarterly installments.